Innate triggering and antiviral effector functions of activin A

5A:2^dCt <i>GAPDH-INHBA</i> expression following transfection of human PBMC (peripheral blood mononuclear cells) with IVT-RNA or poly(I:C) at two doses<br><br>5B:2^dCt <i>GAPDH-MX1</i> expression following transfection of human PBMC with IVT-RNA or poly(I:C) at two doses<br>5C:2^dCt <i>GAPDH-IFI6</i> expression following transfection of human PBMC with IVT-RNA or poly(I:C) at two doses<br>5D:2^dCt <i>GAPDH-INHBA</i> expression following exposure of human PBMC to the imidazoquinolones R848 and R837<br>5E:2^dCt <i>GAPDH-MX1</i> expression following exposure of human PBMC to the imidazoquinolones R848 and R837<br>5F:2^dCt <i>GAPDH-INHBA</i> expression following transfection of human PBMC with ssRNA40 LyoVec (TLR8 agonist)<br><br>5G:2^dCt <i>GAPDH-IFI6</i> expression following transfection of human PBMC with ssRNA40 LyoVec (TLR8 agonist)<br>6A:2^dCt <i>GAPDH-INHBA</i> at 48 hours post-infection in A549.gfp cells infected with increasing titres of Sendai virus (SeV) compared to controls<br>6B:2^dCt <i>GAPDH-MX1</i> at 48 hours post-infection in A549.gfp cells infected with increasing titres of Sendai virus (SeV) compared to controls<br>6C:2^dCt <i>GAPDH-INHBA </i>expression in HuH7 (RIG-I replete) versus HuH7.5 (RIG-I deficient) cells following SeV infection at various multiplicities, assayed at 48 hours post-infection.<br>6D:2^dCt <i>GAPDH-MX1 </i>expression in HuH7 (RIG-I replete) versus HuH7.5 (RIG-I deficient) cells following SeV infection at various multiplicities, assayed at 48 hours post-infection.<br>6E:2^dCt <i>GAPDH-SEV </i>(encoding Sendai virus genomic RNA) expression in HuH7 and HuH7.5 cell lines, assayed at 48 hours post-infection<br>6F:Fold change in <i>INHBA</i> expression, normalized to <i>GAPDH</i>, at 72 hours post-infection in HuH7.5.1 cells relative to uninfected (U.I.) cells.<br>Figure 6G:Fold change in <i>MX1</i> expression, normalized to <i>GAPDH</i>, at 72 hours post-infection in HuH7.5.1 cells relative to uninfected (U.I.) cells.<br>7A:2^dCt <i>Hprt-Inhba</i> expression in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection.<br>p { margin-bottom: 0.25cm; direction: ltr; color: #000000; line-height: 115%; text-align: left; orphans: 2; widows: 2; background: transparent }p.western { font-family: "Liberation Serif", serif; font-size: 12pt; so-language: en-GB }p.cjk { font-family: "Noto Serif CJK SC"; font-size: 12pt; so-language: zh-CN }p.ctl { font-family: "FreeSans"; font-size: 12pt; so-language: hi-IN }<br>7B:2^dCt <i>Hprt-Isg15</i> expression in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection.<br><br>7C:Correlation of <i>Inhba</i> and <i>Isg15</i> transcript induction in the lungs of FLUAV PR/8 infected mice at 72 hours post-infection (linear regression, R² = 0.9271, p=0.002)<br>7D:2^dCt <i>Hprt-Inhba</i> expression in the liver of FLUAV PR/8 infected mice at 72 hours post-infection<br><br>7E:2^dCt <i>Hprt-Isg15</i> expression in the liver of FLUAV PR/8 infected mice at 72 hours post-infection<br>7F:2^dCt <i>Hprt-Inhba</i> induction in the lung tissue of FLUAV PR/8 infected mice at 48 hours post-infection, across a range of increasing multiplicities of infection.<br><br> 7G:2^dCt <i>Hprt-Inhba</i> expression in wildtype or MAVS-depleted mice at 48 hours post-infection with FLUAV PR/8<br>7H:2^dCt <i>Hprt-Isg15</i> expression in wildtype of MAVS-depleted mice at 48 hours post-infection with FLUAV PR/8<br>Supplementary Figure 1A:Fold change <i>INHBA</i> normalized to <i>GAPDH</i> for HuH7 cells exposed to recombinant IFN or control medium (D10)<br>Supplementary Figure 1B/C/D: OR6 cells incubated with a titration of IFNα in the presence of titrating doses of activin A; assayed for Renilla luciferse and Cell Titer Glo activity.<br>